NCT04645797 - A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2021

Primary Completion Date

May 7, 2022

Study Completion Date

May 7, 2022

Conditions

Advanced Colorectal Carcinoma

Interventions

DRUG

APR003

This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.

Trial Locations (4)

28078

Carolina BioOncology Institute Cancer Research Clinic, Huntersville

32803

AdventHealth Orlando, Orlando

78229

NEXT Oncology - San Antonio, San Antonio

78758

NEXT Oncology - Austin, Austin